Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-09-16Clinical Trial Update: Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL [Phase 2]
Phase 2 trial update investigating zanubrutinib in combination with R-CHOP for newly diagnosed untreated non-GCB/ABC diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL [Phase 2]
Phase 2 study of AT13387 (Onalespib) in ALK+ anaplastic large cell lymphoma, mantle cell lymphoma, and BCL-6+ diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2022-08-26Clinical Trial Update: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy [Phase 3]
Phase 3 trial evaluating prephase prednisone +/- vitamin D before immunochemotherapy in elderly patients with diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-08-26Clinical Trial Update: B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 [Phase 4]
Phase 4 clinical trial update for a B-cell mature non-Hodgkin lymphoma treatment protocol in children and adolescents; currently recruiting.
-
CLINICAL_TRIALS trial_result · 2022-08-24Clinical Trial Update: JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial evaluating JCAR014 in combination with Durvalumab for relapsed or refractory B-cell non-Hodgkin lymphoma has been terminated; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-19Clinical Trial Update: SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression [Phase 1, Phase 2]
A Phase 1/2 trial evaluating SPEL as introductory treatment following immunochemotherapy for relapsed/refractory diffuse large B-cell lympho…
-
CLINICAL_TRIALS trial_result · 2022-08-18Clinical Trial Update: Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL [Phase 1, Phase 2]
Phase 1/2 trial of MT-3724 in relapsed or refractory diffuse large B-cell lymphoma and related B-cell hematologic malignancies; the study is…
-
CLINICAL_TRIALS trial_result · 2022-08-16Clinical Trial Update: PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating multiple dose regimens of MT-3724 with gemcitabine and oxaliplatin in relapsed/refractory diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). [Phase 3]
Phase 3 trial comparing Polatuzumab Vedotin plus Bendamustine and Rituximab versus Bendamustine and Rituximab alone in Chinese patients with…
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL [Phase 1, Phase 2]
Phase 1/2 trial evaluating KRT-232 in combination with acalabrutinib for relapsed/refractory DLBCL and CLL; status not disclosed.
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor [Phase 2]
Phase 2 trial evaluating RCHOP chemotherapy with BBB permeabilization by t-NGR necrosis factor in diffuse large B-cell lymphoma; study compl…
-
CLINICAL_TRIALS trial_result · 2022-07-25Clinical Trial Update: ChiCGB vs BEAM in High-risk or R/R Lymphomas [Phase 3]
Phase 3 clinical trial comparing ChiCGB to BEAM in high-risk or refractory/relapsed lymphomas is listed with phase 3 and unknown status.
-
CLINICAL_TRIALS trial_result · 2022-07-22Clinical Trial Update: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL [Phase 2]
Phase 2 trial evaluating acalabrutinib in combination with RICE for relapsed/refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2022-07-21Clinical Trial Update: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma [Phase 2, Phase 3]
Phase 2/3 trial assessing ublituximab + umbralisib with or without bendamustine, and umbralisib alone, in previously treated non-Hodgkin lym…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating axicabtagene ciloleucel as first-line therapy for high-risk diffuse large B-cell lymphoma has completed, with res…
-
CLINICAL_TRIALS trial_result · 2022-07-08Clinical Trial Update: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating orelabrutinib in combination with Gemox for refractory/relapsed diffuse large B-cell lymphoma is underwa…
-
CLINICAL_TRIALS trial_result · 2022-06-28Clinical Trial Update: EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection [Phase 2]
A Phase 2 trial evaluated EPOCH chemotherapy with Rituximab for HIV-associated non-Hodgkin lymphoma, including diffuse large B-cell lymphoma…
-
CLINICAL_TRIALS trial_result · 2022-06-23Clinical Trial Update: The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. [Phase 2]
Phase 2 trial comparing ZR2 to a R-CHOP-like regimen in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma [Phase 2]
Phase 2 trial update for therapy in untreated DLBCL patients across risk groups; study completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial [Phase 2]
A multicenter randomized Phase II trial evaluating treatment options for diffuse large B-cell lymphoma in vulnerable or frail elderly patien…
-
CLINICAL_TRIALS trial_result · 2022-06-08Clinical Trial Update: Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. [Phase 2, Phase 3]
Phase II randomized study comparing BR-DHAP vs R-DHAP induction therapy in relapsed/refractory diffuse large B-cell lymphoma patients eligib…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial [Phase 2]
Phase 2 clinical trial evaluating rituximab plus zanubrutinib and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma; effica…
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion [Phase 2]
Phase 2 trial evaluating addition of nivolumab to anti-CD-19 CAR-T cells in patients with B cell lymphoma undergoing lymphodepletion.
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating laboratory-treated T cells in relapsed or refractory B-cell malignancies and acute lymphoblastic leukemia.
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) [Phase 1]
Phase 1 first-in-human trial of GSK3368715 in solid tumors and diffuse large B-cell lymphoma has been terminated; results posted in 2022.